JANESVILLE, Wis., May 23, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, today announced Chris Vessell has joined as General Manager of the Therapeutics Division. In this role, he will be responsible for developing and building the team dedicated to SHINE’s strategy and offerings around non-carrier-added lutetium-177 for cancer therapies.
A leader in nuclear technology obtains funding to produce medical isotopes in Europe and to help meet growing demands to provide diagnostic imaging for life-threatening diseases on a global scale.
SHINE Medical Technologies LLC, the Institute of Organic Chemistry and Biochemistry (IOCB Prague) and GE Healthcare today announced the production of patient doses of the therapeutic isotope lutetium-177 (Lu-177).
SHINE Medical Technologies and Deerfield Management Company, a healthcare investment firm, announced today the closing of a definitive agreement providing a $150 million financing commitment to support diagnostic and therapeutic medical isotope manufacturing.
January 16, 2017 - SHINE Medical Technologies, Inc. (SHINE), a company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, held a ribbon cutting ceremony to celebrate the grand opening of the company’s new global headquarters in downtown Janesville, Wisconsin. The ribbon cutting was led by the John Beckord and the Forward Janesville Goodwill Ambassadors.
December 12, 2016 - SHINE Medical Technologies announced today that it has been awarded $10 million from the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) as part of a $20.9 million cooperative agreement.
January 11, 2016 - The University of Wisconsin-Madison College of Engineering has awarded Dr. Greg Piefer, founder and CEO of SHINE Medical Technologies, Inc. (SHINE) the Early-Career Achievement Award.
November 9, 2015 - Today, SHINE and GE Healthcare announced they have successfully obtained pharmaceutical-grade Tc‑99m from GE Healthcare’s DRYTEC™ Tc-99m (Kit for the Preparation of Sodium Pertechnetate Technetium Tc99m Injection), using Mo-99 produced by SHINE’s innovative process.